M&T Bank Corp C4 Therapeutics, Inc. Transaction History

M&T Bank Corp

$29.1 Billion
Q2 2024

A detailed history of M&T Bank Corp transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, M&T Bank Corp holds 95,441 shares of CCCC stock, worth $562,147. This represents 0.0% of its overall portfolio holdings.

Number of Shares

95,441

Previous 84,810 12.54%

Holding current value

$562,147

Previous $692,000 36.42%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 31, 2024	BUY	$4.05 - $8.1 $43,055 - $86,111	10,631 Added 12.54%	95,441 $440,000
Q1 2024 May 07, 2024	SELL	$5.3 - $11.0 $285,023 - $591,558	-53,778 Reduced 38.8%	84,810 $692,000
Q4 2023 Feb 06, 2024	SELL	$1.18 - $6.03 $1,689 - $8,634	-1,432 Reduced 1.02%	138,588 $783,000
Q3 2023 Nov 02, 2023	BUY	$1.81 - $3.89 $253,436 - $544,677	140,020 New	140,020 $260,000
Q1 2023 May 11, 2023	BUY	$3.1 - $9.02 $33,194 - $96,586	10,708 Added 17.47%	72,000 $226,000
Q4 2022 Feb 13, 2023	SELL	$5.42 - $10.24 $106,790 - $201,758	-19,703 Reduced 38.52%	31,447 $185,000
Q4 2022 Feb 13, 2023	BUY	$5.42 - $10.24 $161,759 - $305,612	29,845 Added 94.91%	61,292 $361,000
Q3 2022 Nov 14, 2022	SELL	$8.03 - $12.77 $87,077 - $138,477	-10,844 Reduced 17.49%	51,150 $448,000
Q2 2022 Aug 05, 2022	BUY	$5.06 - $26.46 $225,908 - $1.18 Million	44,646 Added 257.36%	61,994 $468,000
Q1 2022 May 09, 2022	BUY	$19.99 - $33.23 $198,780 - $330,439	9,944 Added 134.31%	17,348 $420,000
Q4 2021 Feb 07, 2022	BUY	$29.39 - $46.86 $42,527 - $67,806	1,447 Added 24.29%	7,404 $238,000
Q3 2021 Oct 28, 2021	SELL	$35.91 - $50.5 $1,472 - $2,070	-41 Reduced 0.68%	5,957 $266,000
Q2 2021 Aug 13, 2021	BUY	$30.39 - $42.18 $182,279 - $252,995	5,998 New	5,998 $227,000

Others Institutions Holding CCCC

# of Institutions

119

Shares Held

53.8M

Call Options Held

331K

Put Options Held

145K

View Full List

About C4 Therapeutics, Inc.

Ticker CCCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,913,800
Market Cap $288M
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...

More about CCCC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of M&T Bank Corp, based on Form 13F filings with the SEC.

News

Stay updated on M&T Bank Corp with notifications on news.

Account